Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Small Cell Lung Carcinoma 1Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Acrocephalosyndactylia 1

Interventions

pembrolizumab 18Nivolumab 12atezolizumab 5Ipilimumab 4Cyclophosphamide 4fludarabine 3Paclitaxel 3Magnetic Resonance Spectroscopy 3Fluorodeoxyglucose F18 3Docetaxel 3Carboplatin 3spartalizumab 2cabozantinib 2avelumab 2aldesleukin 2Specimen Handling 2Interleukin-2 2Immunoglobulin G 2zanidatamab 1veliparib 1trastuzumab deruxtecan 1tislelizumab 1temsirolimus 1sargramostim 1sacituzumab govitecan 1rucaparib 1regorafenib 1poly ICLC 1pemigatinib 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Drug Combinations × Breast × Clear all
NCT04125693 2022-04-01

Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety

Bayer

Phase 2 Completed
1 enrolled
BreastGenitourinaryHead & NeckThoracic

Acrocephalosyndactylia, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡